{"id":"W4406087364","doi":"10.1007/s40257-024-00909-5","title":"A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis","year":2025,"lang":"en","type":"article","venue":"American Journal of Clinical Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"Incyte","keywords":"Medicine; Ruxolitinib; Adverse effect; Atopic dermatitis; Tolerability; Janus kinase inhibitor; Eczema Area and Severity Index; Internal medicine; Clinical endpoint; Quality of life (healthcare); Pharmacokinetics; Body surface area; Clinical trial; Tofacitinib; Dermatology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001070238,0.0005252595,0.001200965,0.0001482784,0.0003048405,0.0003743214,0.0003199009,0.0005384443,0.001349818],"category_scores_gemma":[0.0006793009,0.0002545866,0.0009784101,0.000181688,0.0002787907,0.0003669373,0.0002637149,0.001313769,0.0001879481],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004494913,"about_ca_system_score_gemma":0.0005633525,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006607767,"about_ca_topic_score_gemma":0.001961495,"domain_scores_codex":[0.9995975,0.0002098384,0.0000279391,0.00004889321,0.00004483425,0.00007110467],"domain_scores_gemma":[0.999593,0.0001252831,0.0001030929,0.0000195309,0.00002562749,0.0001335495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6641226,0.04397834,0.06927833,0.002338145,0.002459506,0.002941216,0.0008209711,0.001853183,0.0504287,0.0003026241,0.002796029,0.1586803],"study_design_scores_gemma":[0.2356044,0.5009991,0.2444904,0.0001725833,0.001149688,0.002565499,0.0002780729,0.001266697,0.0069483,0.00008195625,0.006400064,0.00004326533],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997612,0.001522313,0.00006712042,0.00006550589,0.00002100949,0.0001813498,0.0001108537,0.00000639728,0.0004134036],"genre_scores_gemma":[0.9975005,0.001157607,0.0002872936,0.00015646,0.00005218705,0.0002247018,0.0002617438,0.000003462218,0.0003559797],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001349818,"threshold_uncertainty_score":0.005659997,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01936643116546527,"score_gpt":0.3473711334280457,"score_spread":0.3280047022625804,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}